Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 63 EUR 1.86% Market Closed
Market Cap: 3.2B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Laboratorios Farmaceuticos ROVI SA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laboratorios Farmaceuticos ROVI SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Pre-Tax Income
€280.1m
CAGR 3-Years
13%
CAGR 5-Years
40%
CAGR 10-Years
27%
Almirall SA
MAD:ALM
Pre-Tax Income
-€1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
29%
F
Faes Farma SA
MAD:FAE
Pre-Tax Income
€145.6m
CAGR 3-Years
20%
CAGR 5-Years
7%
CAGR 10-Years
18%
Laboratorio Reig Jofre SA
MAD:RJF
Pre-Tax Income
€13.3m
CAGR 3-Years
29%
CAGR 5-Years
3%
CAGR 10-Years
24%
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.3B EUR
Industry
Pharmaceuticals

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid and currently employs 1,751 full-time employees. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

ROVI Intrinsic Value
83.93 EUR
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income?
Pre-Tax Income
280.1m EUR

Based on the financial report for Sep 30, 2024, Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income amounts to 280.1m EUR.

What is Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
27%

Over the last year, the Pre-Tax Income growth was -24%. The average annual Pre-Tax Income growth rates for Laboratorios Farmaceuticos ROVI SA have been 13% over the past three years , 40% over the past five years , and 27% over the past ten years .

Back to Top